Rituximab exerts a dual effect in pemphigus vulgaris
- PMID: 18563178
- DOI: 10.1038/jid.2008.172
Rituximab exerts a dual effect in pemphigus vulgaris
Abstract
Pemphigus vulgaris (PV) is a severe autoimmune blistering disease affecting the skin and mucous membranes. Autoreactive CD4(+) T helper (Th) lymphocytes are crucial for the autoantibody response against the desmosomal adhesion molecules, desmoglein (dsg)-3 and dsg1. Eleven patients with extensive PV were treated with the anti-CD20 antibody, rituximab (375 mg per m(2) body surface area once weekly for 4 weeks). Frequencies of autoreactive CD4(+) Th cells in the peripheral blood of the PV patients were determined 0, 1, 3, 6, and 12 months after rituximab treatment. Additionally, the clinical response was evaluated and serum autoantibody titers were quantified by ELISA. Rituximab induced peripheral B-cell depletion for 6-12 months, leading to a dramatic decline of serum autoantibodies and significant clinical improvement in all PV patients. The frequencies of dsg3-specific CD4(+) Th1 and Th2 cells decreased significantly for 6 and 12 months, respectively, while the overall count of CD3(+)CD4(+) T lymphocytes and the frequency of tetanus toxoid-reactive CD4(+) Th cells remained unaffected. Our findings indicate that the response to rituximab in PV involves two mechanisms: (1) the depletion of autoreactive B cells and (2) the herein demonstrated, presumably specific downregulation of dsg3-specific CD4(+) Th cells.
Comment in
-
Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.J Invest Dermatol. 2008 Dec;128(12):2745-7. doi: 10.1038/jid.2008.330. J Invest Dermatol. 2008. PMID: 18997839
Similar articles
-
Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.J Invest Dermatol. 2009 Sep;129(9):2202-10. doi: 10.1038/jid.2009.27. Epub 2009 Mar 12. J Invest Dermatol. 2009. PMID: 19282839
-
The emergence of circulating activated autoreactive desmoglein 3-specific follicular regulatory T cells is associated with long-term efficacy of rituximab in patients with pemphigus vulgaris.Br J Dermatol. 2024 Sep 18;191(4):605-615. doi: 10.1093/bjd/ljae220. Br J Dermatol. 2024. PMID: 38848544
-
Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).Dermatology. 2007;214(4):310-8. doi: 10.1159/000099591. Dermatology. 2007. PMID: 17460402
-
Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.J Dermatol. 1999 Nov;26(11):748-52. doi: 10.1111/j.1346-8138.1999.tb02086.x. J Dermatol. 1999. PMID: 10635617 Review.
-
Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.Exp Dermatol. 2013 Nov;22(11):699-704. doi: 10.1111/exd.12229. Exp Dermatol. 2013. PMID: 24433179 Review.
Cited by
-
Off-Label Uses of Rituximab in Dermatology.Curr Dermatol Rep. 2022;11(4):209-220. doi: 10.1007/s13671-022-00375-4. Epub 2022 Oct 6. Curr Dermatol Rep. 2022. PMID: 36217351 Free PMC article. Review.
-
Novel applications of Rituximab in dermatological disorders.Indian Dermatol Online J. 2014 Jul;5(3):250-9. doi: 10.4103/2229-5178.137766. Indian Dermatol Online J. 2014. PMID: 25165639 Free PMC article. Review.
-
A small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupus.J Exp Med. 2011 Dec 19;208(13):2591-8. doi: 10.1084/jem.20110978. Epub 2011 Nov 21. J Exp Med. 2011. PMID: 22110167 Free PMC article. Clinical Trial.
-
Management of Pemphigus Vulgaris.Adv Ther. 2016 Jun;33(6):910-58. doi: 10.1007/s12325-016-0343-4. Epub 2016 Jun 10. Adv Ther. 2016. PMID: 27287854 Free PMC article. Review.
-
Pemphigus vulgaris.An Bras Dermatol. 2019 Jul 29;94(3):264-278. doi: 10.1590/abd1806-4841.20199011. An Bras Dermatol. 2019. PMID: 31365654 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous